Frequently Asked Questions
The market is segmented based on , By Drug Class (Biguanides, Thiazolidinediones, Dipeptidyl Peptidase IV Inhibitors, α-Glucosidase Inhibitors, Insulin Secretagogues, Amylin Analog, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
.
The Global Oral Antidiabetic Drugs Market size was valued at USD 45.00 USD Billion in 2021.
The Global Oral Antidiabetic Drugs Market is projected to grow at a CAGR of 3% during the forecast period of 2022 to 2029.
The major players operating in the market include Pfizer , F. Hoffmann La Roche Ltd, Mylan N.V., Fresenius Kabi AG, Novartis AG, Teva Pharmaceutical Industries , Bristol Myers Squibb Company, GSK Plc., Bayer AG.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
